The role of hyperhomocysteinemia as well as folate, vitamin B6 and B12 deficiencies in osteoporosis - A systematic review

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 12, 2007, Pages 1621-1632

  Herrmann, Markus ^a,b,e   Peter Schmidt, Johannes ^b   Umanskaya, Natalia ^b   Wagner, Alexandra ^b   Taban Shomal, Omid ^b   Widmann, Thomas ^b   Colaianni, Graziana ^c   Wildemann, Britt ^d   Herrmann, Wolfgang ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SAARLAND UNIVERSITY   (Germany)

^c UNIVERSITY OF BARI   (Italy)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e ANZAC RESEARCH INSTITUTE   (Australia)

Author keywords

Bone metabolism; Folate; Homocysteine; Osteoporosis; Vitamin B12; Vitamin B6

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; PYRIDOXINE;

BONE DENSITY; BONE METABOLISM; BONE RESECTION; BONE TURNOVER; CELL CULTURE; CLINICAL TRIAL; CONFERENCE PAPER; CYANOCOBALAMIN DEFICIENCY; DISEASE ASSOCIATION; FOLIC ACID DEFICIENCY; HIP FRACTURE; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RISK REDUCTION;

ANIMALS; BONE DENSITY; FOLIC ACID DEFICIENCY; FRACTURES, BONE; HUMANS; HYPERHOMOCYSTEINEMIA; OSTEOPOROSIS; VITAMIN B 12; VITAMIN B 6; VITAMIN B DEFICIENCY;

ANIMALIA;

EID: 36849056638     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.362     Document Type: Conference Paper

References (93)

1. Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, Weger M. DACH-LIGA Homocystein eV (German, Austrian and Swiss homocysteine society): consensus paper on the rational clinical use of Homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med 2003;41:1392-403.
2. Herrmann M, Stanger O, Paulweber B, Hufnagl C, Herrmann W. Effect of folate supplementation on N-terminal pro-brain natriuretic peptide. Int J Cardiol 2007;118:267-9.
3. Clarke R, Refsum H, Birks J, Evans JG, Johnston C, Sherliker P, et al. Screening for vitamin B-12 and folate deficiency in older persons. Am J Clin Nutr 2003;77:1241-7.
4. Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem 2004;50:3-32.
5. de Bree A, Verschuren WM, Blom HJ, Kromhout D. Lifestyle factors and plasma homocysteine concentrations in a general population sample. Am J Epidemiol 2001;154:150-4.
6. Herrmann W, Quast S, Ullrich M, Schultze H, Bodis M, Geisel J. Hyperhomocysteinemia in high-aged subjects: relation of B-vitamins, folic acid, renal function and the methylenetetrahydrofolate reductase mutation. Atherosclerosis 1999;144:91-101.
7. Dholakia KR, Dharmarajan TS, Yadav D, Oiseth S, Norkus EP, Pitchumoni CS. Vitamin B12 deficiency and gastric histopathology in older patients. World J Gastroenterol 2005;11:7078-83.
8. van Oijen MG, Sipponen P, Laheij RJ, Verheugt FW, Jansen JB. Gastric status and vitamin B12 levels in cardiovascular patients. Dig Dis Sci 2007;52:2186-9.
9. van Meurs JB, Dhonukshe-Rutten RA, Pluijm SM, van der Klifs M, de Jonge R, Lindemans J, et al. Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med 2004;350:2033-41.
10. McLean RR, Jacques PF, Selhub J, Tucker KL, Samelson EJ, Broe KE, et al. Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med 2004;350:2042-9.
11. Who are candidates for prevention and treatment for osteoporosis? [No authors listed] Osteoporos Int 1997;7:1-6.
12. Lippuner K, Golder M, Greiner R. Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland. Osteoporos Int 2005;16(Suppl 2):S8-17.
13. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002;359:1761-7.
14. Melton LJ III. Adverse outcomes of osteoporotic fractures in the general population. J Bone Miner Res 2003;18:1139-41.
15. Walker-Bone K, Walter G, Cooper C. Recent developments in the epidemiology of osteoporosis. Curr Opin Rheumatol 2002;14:411-5.
16. Homocysteine Trialist's Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005;82:806-12.
17. Clarke R, Lewington S, Sherliker P, Armitage J. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Curr Opin Clin Nutr Metab Care 2007;10:32-9.
18. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
19. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999;353:878-82.
20. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129.
21. Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Meyer HE, Grethe ST. Plasma homocysteine, folate, and vitamin B12 and the risk of hip fracture: the Hordaland Homocysteine Study. J Bone Miner Res 2007;22:747-56.
22. Hong X, Hsu YH, Terwedow H, Tang G, Liu X, Jiang S, et al. Association of the methylenetetrahydrofolate reductase C677T polymorphism and fracture risk in Chinese postmenopausal women. Bone 2007;40:737-42.
23. Baines M, Kredan MB, Usher J, Davison A, Higgins G, Taylor W, et al. The association of homocysteine and its determinants MTHFR genotype, folate, vitamin B12 and vitamin B6 with bone mineral density in postmenopausal British women. Bone 2007;40:730-6.
24. Perier MA, Gineyts E, Munoz F, Sornay-Rendu E, Delmas PD. Homocysteine and fracture risk in postmenopausal women: the OFELY study. Osteoporos Int 2007;18:1329-36.
25. Kim DJ, Park BL, Koh JM, Kim GS, Kim LH, Cheong HS, et al. Methionine synthase reductase polymorphisms are associated with serum osteocalcin levels in postmenopausal women. Exp Mol Med 2006;38:519-24.
26. Gerdhem P, Ivaska KK, Isaksson A, Pettersson K, Vaananen HK, Obrant KJ, et al. Associations between homocysteine, bone turnover, BMD, mortality, and fracture risk in elderly women. J Bone Miner Res 2007;22:127-34.
27. Gjesdal CG, Vollset SE, Ueland PM, Refsum H, Drevon CA, Gjessing HK, et al. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch Intern Med 2006;166:88-94.
28. Herrmann M, Kraenzlin M, Pape G, Sand-Hill M, Herrmann W. Relation between homocysteine and biochemical bone turnover markers and bone mineral density in peri- and post-menopausal women. Clin Chem Lab Med 2005;43:1118-23.
29. Ravaglia G, Forti P, Maioli F, Servadei L, Martelli M, Brunetti N, et al. Folate, but not homocysteine, predicts the risk of fracture in elderly persons. J Gerontol A Biol Sci Med Sci 2005;60:1458-62.
30. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 2005;118:1250-5.
31. Abrahamsen B, Jorgensen HL, Nielsen TL, Andersen M, Haug E, Schwarz P, et al. MTHFR c.677C> T polymorphism as an independent predictor of peak bone mass in Danish men - results from the Odense Androgen Study. Bone 2006;38:215-9.
32. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone 2005;37:234-42.
33. Dhonukshe-Rutten RA, Pluijm SM, de Groot LC, Lips P, Smit JH, van Staveren WA. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband ultrasound attenuation, and fractures in healthy elderly people. J Bone Miner Res 2005;20:921-9.
34. Villadsen MM, Bunger MH, Carstens M, Stenkjaer L, Langdahl BL. Methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism is associated with osteoporotic vertebral fractures, but is a weak predictor of BMD. Osteoporos Int 2005;16:411-6.
35. Nilsson K, Gustafson L, Isaksson A, Hultberg B. Plasma homocysteine and markers of bone metabolism in psychogeriatric patients. Scand J Clin Lab Invest 2005;65:671-80.
36. Macdonald HM, McGuigan FE, Fraser WD, New SA, Ralston SH, Reid DM. Methylenetetrahydrofolate reductase polymorphism interacts with riboflavin intake to influence bone mineral density. Bone 2004;35:957-64.
37. Li M, Lau EM, Woo J. Methylenetetrahydrofolate reductase polymorphism (MTHFR C677T) and bone mineral density in Chinese men and women. Bone 2004;35:1369-74.
38. Bathum L, von Bornemann HJ, Christiansen L, Madsen JS, Skytthe A, Christensen K. Evidence for an association of methylene tetrahydrofolate reductase polymorphism C677T and an increased risk of fractures: results from a population-based Danish twin study. Osteoporos Int 2004;15:659-64.
39. Golbahar J, Hamidi A, Aminzadeh MA, Omrani GR. Association of plasma folate, plasma total homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in post-menopausal Iranian women: a cross-sectional study. Bone 2004;35:760-5.
40. Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A. Relation of homocysteine, folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 2003;33:956-9.
41. Miyao M, Morita H, Hosoi T, Kurihara H, Inoue S, Hoshino S, et al. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif Tissue Int 2000;66:190-4.
42. Bode MK, Laitinen P, Risteli J, Uusimaa P, Juvonen T. Atherosclerosis, type 1 collagen cross-linking and homocysteine. Atherosclerosis 2000;152:531-2.
43. McLean M, McGowan TS, Catton CN, Catton PA, Panzarella T. The impact of prostatic manipulation upon serum PSA in patients with adenocarcinoma of the prostate. Clin Oncol (R Coll Radiol) 1993;5:293-6.
44. Cummings SR, Bates D, Black DM. Clinical use of bone densitometry: scientific review. J Am Med Assoc 2002;288:1889-97.
45. Kanis JA, Black D, Cooper C, Dargent P, Dawson-Hughes B, De Laet C, et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 2002;13:527-36.
46. Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, et al. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999;21:1025-44.
47. Riancho JA, Valero C, Zarrabeitia MT. MTHFR polymorphism and bone mineral density: meta-analysis of published studies. Calcif Tissue Int 2006;79:289-93.
48. Small RE. Uses and limitations of bone mineral density measurements in the management of osteoporosis. MedGenMed 2005;7:3.
49. Briot K, Roux C. What is the role of DXA, QUS and bone markers in fracture prediction, treatment allocation and monitoring? Best Pract Res Clin Rheumatol 2005;19:951-64.
50. Gonzalez-Gross M, Sola R, Albers U, Barrios L, Alder M, Castillo MJ, et al. B-vitamins and homocysteine in Spanish institutionalized elderly. Int J Vitam Nutr Res 2007;77:22-33.
51. Golbahar J, Aminzadeh MA, Hamidi SA, Omrani GR. Association of red blood cell 5-methyltetrahydrofolate folate with bone mineral density in postmenopausal Iranian women. Osteoporos Int 2005;16:1894-8.
52. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in stroke patients. Bone 2005;36:721-6.
53. Tucker KL, Hannan MT, Qiao N, Jacques PF, Selhub J, Cupples LA, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res 2005;20:152-8.
54. Dhonukshe-Rutten RA, Lips M, de Jong N, Chin AP, Hiddink GJ, van Dusseldorp M, et al. Vitamin B-12 status is associated with bone mineral content and bone mineral density in frail elderly women but not in men. J Nutr 2003;133:801-7.
55. Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 2002;167:S1-34.
56. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J. The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 2000;11(Suppl 6):S2-17.
57. Garnero P, Hausherr E, Chapuy MC, Marcelli C, Grandjean H, Muller C, et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996;11:1531-8.
58. Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, et al. Clinical use of biochemical markers of bone remodeling: current status and future directions. Osteoporos Int 2000;11:467-80.
59. Seibel MJ. Biochemical markers of bone remodeling. Endocrinol Metab Clin North Am 2003;32:83-113.
60. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev 2005;26:97-122.
61. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-62.
62. Lippi G, Brocco G, Salvagno GL, Montagnana M, Guidi GC, Schmidt-Gayk H. Influence of the sample matrix on the stability of beta-CTX at room temperature for 24 and 48 hours. Clin Lab 2007;53:455-9.
63. Seibel MJ. Molecular markers of bone turnover: biochemical, technical and analytical aspects. Osteoporos Int 2000;11(Suppl 6):S18-29.
64. Green TJ, McMahon JA, Skeaff CM, Williams SM, Whiting SJ. Lowering homocysteine with B vitamins has no effect on biomarkers of bone turnover in older persons: a 2-y randomized controlled trial. Am J Clin Nutr 2007;85:460-4.
65. Herrmann M, Stanger O, Paulweber B, Hufnagl C, Herrmann W. Folate supplementation does not affect biochemical markers of bone turnover. Clin Lab 2006;52:131-6.
66. Herrmann M, Umanskaya N, Traber L, Schmidt-Gayk H, Menke W, Lanzer G, et al. The effect of B-vitamins on biochemical bone turnover markers and bone mineral density in osteoporotic patients - a one year double blind placebo controlled trial. Clin Chem Lab Med 2007;45:1785-92.
67. Sato Y, Honda Y, Iwamoto J, Kanoko T, Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke: a randomized controlled trial. J Am Med Assoc 2005;293:1082-8.
68. van Meurs JB, Uitterlinden AG. Homocysteine and fracture prevention. J Am Med Assoc 2005;293:1121-2.
69. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
70. Lonn E, Yusuf S, Arnold MJ, Sheridan P, Pogue J, Micks M, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
71. Özdem S, Samanci N, Tasatargil A, Yildiz A, Sadan G, Donmez L, et al. Experimental hyperhomocysteinemia disturbs bone metabolism in rats. Scand J Clin Lab Invest 2007;E-pub ahead of print.
72. Herrmann M, Wildemann B, Claes L, Klohs S, Ohnmacht M, Taban-Shomal O, et al. Experimental hyperhomocysteinemia reduces bone quality in rats. Clin Chem 2007; 53:1455-61.
73. Masse PG, Boskey AL, Ziv I, Hauschka P, Donovan SM, Howell DS, et al. Chemical and biomechanical characterization of hyperhomocysteinemic bone disease in an animal model. BMC Musculoskelet Disord 2003;4:2.
74. Herrmann M, Widmann T, Colaianni G, Colucci S, Zallone A, Herrmann W. Increased osteoclast activity in the presence of increased homocysteine concentrations. Clin Chem 2005;51:2348-53.
75. Koh JM, Lee YS, Kim YS, Kim DJ, Kim HH, Park JY, et al. Homocysteine enhances bone resorption by stimulation of osteoclast formation and activity through increased intracellular ROS generation. J Bone Miner Res 2006;21:1003-11.
76. Herrmann M, Umanskaya N, Wildemann B, Colaianni G, Widmann T, Zallone A, et al. Stimulation of osteoblast activity by homocysteine. J Cell Mol Med 2007. In press.
77. Kim DJ, Koh JM, Lee O, Kim NJ, Lee YS, Kim YS, et al. Homocysteine enhances apoptosis in human bone marrow stromal cells. Bone 2006;39:582-90.
78. Sakamoto W, Isomura H, Fujie K, Deyama Y, Kato A, Nishihira J, et al. Homocysteine attenuates the expression of osteocalcin but enhances osteopontin in MC3T3-E1 preosteoblastic cells. Biochim Biophys Acta 2005;1740:12-6.
79. Carmel R, Lau KH, Baylink DJ, Saxena S, Singer FR. Cobalamin and osteoblast-specific proteins. N Engl J Med 1988;319:70-5.
80. Oxlund H, Barckman M, Ortoft G, Andreassen TT. Reduced concentrations of collagen cross-links are associated with reduced strength of bone. Bone 1995;17:365-71S.
81. Oxlund H, Mosekilde L, Ortoft G. Reduced concentration of collagen reducible cross links in human trabecular bone with respect to age and osteoporosis. Bone 1996;19:479-84.
82. Banse X, Sims TJ, Bailey AJ. Mechanical properties of adult vertebral cancellous bone: correlation with collagen intermolecular cross-links. J Bone Miner Res 2002;17:1621-8.
83. Banse X, Devogelaer JP, Lafosse A, Sims TJ, Grynpas M, Bailey AJ. Cross-link profile of bone collagen correlates with structural organization of trabeculae. Bone 2002;31:70-6.
84. McKusick VA. Heritable disorders of connective tissue. St. Louis, MO: Mosby CV, 1966:155 pp.
85. Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int 2006;79:160-8.
86. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone 2001;28:195-201.
87. Lubec B, Fang-Kircher S, Lubec T, Blom HJ, Boers GH. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1996;1315:159-62.
88. Herrmann M, Widmann T, Herrmann W. Re: "Elevated serum homocysteine and McKusick's hypothesis of a disturbed collagen cross-linking: What do we really know?" Bone 2006;39:1385-6.
89. Raposo B, Rodriguez C, Martinez-Gonzalez J, Badimon L. High levels of homocysteine inhibit lysyl oxidase (LOX) and downregulate LOX expression in vascular endothelial cells. Atherosclerosis 2004;177:1-8.
90. Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem 1997;272:32370-7.
91. Bird TA, Levene CI. Lysyl oxidase: evidence that pyridoxal phosphate is a cofactor. Biochem Biophys Res Commun 1982;108:1172-80.
92. Levene CI, Sharman DF, Callingham BA. Inhibition of chick embryo lysyl oxidase by various lathyrogens and the antagonistic effect of pyridoxal. Int J Exp Pathol 1992;73:613-24.
93. Hill CH, Mecham R, Starcher B. Fibrillin-2 defects impair elastic fiber assembly in a homocysteinemic chick model. J Nutr 2002;132:2143-50.